Across TCGA pan-cancer cohorts, LINC02882 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LINC02882 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LINC02882 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LINC02882 expression acts as an unfavorable survival marker.
LIHC are the cancer types where LINC02882 Mutation most reproducibly stratifies survival.